Merck antifungal licensed

Published: 2-Mar-2001


The FDA has approved Merck & Co's caspofungin acetate (Cancidas) to treat invasive aspergillosis in patients who do not respond to or cannot tolerate other antifungal therapies. The drug is the first in a new class, glucan synthesis inhibitors.

You may also like